<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006078</url>
  </required_header>
  <id_info>
    <org_study_id>UIC-H-99-058</org_study_id>
    <secondary_id>CDR0000067915</secondary_id>
    <secondary_id>UIC-N01-CN-85081</secondary_id>
    <secondary_id>NCI-P00-0143</secondary_id>
    <nct_id>NCT00006078</nct_id>
  </id_info>
  <brief_title>Lycopene In Preventing of Prostate Cancer</brief_title>
  <official_title>Single Dose Pharmacokinetic Study of Lycopene Delivered in a Well Defined Food-Based Lycopene Delivery System (Tomato Paste-oil Mixture) in Healthy Male Volunteers Between 18 and 45 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the&#xD;
      development of cancer. The use of lycopene may be an effective way to prevent prostate&#xD;
      cancer.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of lycopene in preventing prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine any dose limiting toxicities and the maximum tolerated dose of lycopene&#xD;
           administered orally as a food based delivery system in healthy male subjects 18-45 years&#xD;
           of age for the chemoprevention of prostate cancer.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this regimen in this population.&#xD;
&#xD;
        -  Determine the dose range of this regimen to be used in the 3 month multiple dose study,&#xD;
           based on the toxicity, pharmacokinetics and feasibility resulting from the present study&#xD;
           in this population.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive a single dose of oral lycopene in a mixture of tomato paste, water, and&#xD;
      olive oil over 15 minutes on day 1. Patients are asked to maintain a diet that contains&#xD;
      negligible carotinoid for 28 days.&#xD;
&#xD;
      Cohorts of 5 patients receive escalating doses of lycopene until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 5 patients&#xD;
      experience dose limiting toxicities.&#xD;
&#xD;
      Patients are followed weekly for 4 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 5-25 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2000</start_date>
  <completion_date type="Actual">January 2005</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Prevention</primary_purpose>
  </study_design_info>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>lycopene</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Normal healthy males judged to be in good medical condition based on history and&#xD;
             physical exam confirming the absence of chronic medical conditions&#xD;
&#xD;
          -  Baseline serum lycopene less than 600 nM&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 to 45&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Hematologic function normal&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Liver function normal&#xD;
&#xD;
          -  No hepatic disease&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Kidney function normal&#xD;
&#xD;
          -  No renal disease&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No hypertension requiring medication&#xD;
&#xD;
          -  No cardiovascular disease&#xD;
&#xD;
          -  Normal EKG&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No evidence of a psychiatric disorder&#xD;
&#xD;
          -  Must be within 15% of ideal body weight based on standard weight tables&#xD;
&#xD;
          -  No history of smoking within the past 3 months&#xD;
&#xD;
          -  At least 72 hours since prior alcohol consumption and no history of alcohol abuse&#xD;
&#xD;
          -  No history of gastrointestinal malabsorption or any other condition that could affect&#xD;
             drug absorption&#xD;
&#xD;
          -  No allergy to tomato based products&#xD;
&#xD;
          -  No active malignancy at any site&#xD;
&#xD;
          -  No illness that would pose a threat or additional risk (e.g., thyroid disease,&#xD;
             diabetes mellitus)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 14 days since prior prescription drugs&#xD;
&#xD;
          -  No concurrent regular prescription medications&#xD;
&#xD;
          -  At least 30 days since other prior experimental drugs&#xD;
&#xD;
          -  No concurrent participation in any other experimental trial&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith A. Rodvold</last_name>
    <role>Study Chair</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Illinois Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2004</verification_date>
  <study_first_submitted>August 3, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 25, 2013</last_update_submitted>
  <last_update_submitted_qc>June 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2013</last_update_posted>
  <keyword>prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lycopene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

